Tamsulosin (cas 106133-20-4) attenuates abdominal aortic aneurysm growth
-
Add time:07/23/2019 Source:sciencedirect.com
BackgroundTamsulosin (cas 106133-20-4), an α1A-adrenergic receptor inhibitor, is prescribed to treat benign prostatic hyperplasia in men >60 years of age, the same demographic most susceptible to abdominal aortic aneurysm. The goal of this study was to investigate the effect of tamsulosin on abdominal aortic aneurysm pathogenesis.
We also recommend Trading Suppliers and Manufacturers of Tamsulosin (cas 106133-20-4). Pls Click Website Link as below: cas 106133-20-4 suppliers
Prev:The AAHKS Clinical Research Award: Prophylactic Tamsulosin (cas 106133-20-4) Does Not Reduce the Risk of Urinary Retention Following Lower Extremity Arthroplasty: A Double-Blinded Randomized Controlled Trial
Next:Evolution in the Risk of Cataract Surgical Complications among Patients Exposed to Tamsulosin (cas 106133-20-4)) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Evolution in the Risk of Cataract Surgical Complications among Patients Exposed to Tamsulosin (cas 106133-20-4)07/24/2019
- The AAHKS Clinical Research Award: Prophylactic Tamsulosin (cas 106133-20-4) Does Not Reduce the Risk of Urinary Retention Following Lower Extremity Arthroplasty: A Double-Blinded Randomized Controlled Trial07/22/2019
-
Health and Chemical more >
-
Related Products